Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

Taurine and Reduced Hemoglobin A1c

Research synthesisModerate evidenceMixed effect size3 studies · 2 beneficial · 1 neutral · 0 harmful

Across 3 studies (including two meta-analyses), 2 reported beneficial effects on reducing hemoglobin A1c, with effect sizes ranging from small to moderate; one randomized controlled trial protocol reported a neutral finding (not yet completed). The most-studied dose was 3 g/day, and the median study duration was 180 days. Evidence primarily comes from meta-analyses of clinical trials in populations with metabolic dysfunction or overweight/obesity.

  • Effective dose range: 3 g/day
  • Studied populations: adults with overweight or obesity; individuals with metabolic dysfunction (including long COVID)

Caveats: Evidence base is small (only 3 studies, two of which are meta-analyses) — conclusions should be considered preliminary. One study is a protocol for a randomized controlled trial with a neutral finding that has not yet been completed, so the evidence is weighted toward meta-analyses. The meta-analyses may include overlapping primary studies, and effect sizes varied from small to moderate.

Generated Jul 12, 2026
Doses used in studies
  • g/day: 3 (median 3, IQR 3–3) — 2 studies
  • mg/day: 3,000 (median 3,000, IQR 3,000–3,000) — 1 study
Time to effect
Median: 6 months · IQR 6 months–6 months · Range 6 months–6 months — Reported in 1 of 3 studies
Safety in these studies
3 of 3 papers
Back to top